Abstract: The present disclosure discloses a method for inhibiting formation of a biofilm of bacteria. Specifically, the method may include treating the bacteria with an effective amount of a coumarin-chalcone compound. While inhibiting the formation of the biofilm of the bacteria, the effective amount of the coumarin-chalcone compound may reduce virulences of the bacteria and enhance a susceptibility of the bacteria to an antibiotic when applied in combination with the antibiotic. The present disclosure further discloses a composition including an effective amount of the coumarin-chalcone compound. The composition may be used to inhibit the formation of the biofilm of bacteria. The composition may also include an antibiotic, a minimal inhibitory concentration and a minimal biofilm eliminate concentration of which are reduced when the composition is used.

Abstract: The present disclosure discloses a method for inhibiting formation of a biofilm of bacteria. Specifically, the method may include treating the bacteria with an effective amount of a coumarin-chalcone compound. While inhibiting the formation of the biofilm of the bacteria, the effective amount of the coumarin-chalcone compound may reduce virulences of the bacteria and enhance a susceptibility of the bacteria to an antibiotic when applied in combination with the antibiotic. The present disclosure further discloses a composition including an effective amount of the coumarin-chalcone compound. The composition may be used to inhibit the formation of the biofilm of bacteria. The composition may also include an antibiotic, a minimal inhibitory concentration and a minimal biofilm eliminate concentration of which are reduced when the composition is used.

Abstract: Methods for removing, reducing, dispersing, disrupting or eradicating biofilms present on a surface may include contacting the biofilm with a composition including an agent that reduces the potency of an aminopeptidase in the biofilm. The agent may reduce expression, secretion or extracellular activity of the aminopeptidase in the biofilm. The biofilm may be formed by P. aeruginosa or P. stutzeri. The composition may enhance the sensitivity of P. aeruginosa to ciprofloxacin. Methods of determining the number of bacterial population in biofilm or a culture containing bacterial aggregate may include dispersing the bacterial aggregate or biofilm by using a composition comprising exogenous PslG. The number of bacteria may be determined based on the dispersed bacteria.